Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead
Merck & Co’s stock ended Tuesday 0.57% higher, closing at $109.45, supported by long-term data on a personalized melanoma vaccine it’s working on with Moderna, which helped steady investor sentiment as the session wrapped up.
